TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02957591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx®
Description: Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
Study: NCT04221698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait retraining
Description: 5 gait retraining sessions of continuous feedback in real time during running sessions; using videotape feedback, a digital metronome to increase step rate, and verbal feedback to reduce the tendency to heel strike upon ground contact. Verbal feedback is offered during the 25- to 30-minute running sessions following a series of drills aimed at improving running mechanics.
Study: NCT02703415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: caudal block with bupivacaine (0.25%) 1mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: caudal block with bupivacaine (0.25%) 1mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: caudal block with tramadol 1 mg/kg
Study: NCT01591967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activator IV Adjusting Instrument
Description: Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
Study: NCT02704338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regulatory T cells
Description: Regulatory t cells will be injected back to autoimmune hepatitis patients
Study: NCT00517751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-STOP PEEK
Description: Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
Study: NCT00314353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV Day 1 every 21 days for eight cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 200 mg/m2 IV Day 1 every 21 days for eight cycles
Study: NCT02710136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycerinated German Cockroach Allergenic Extract
Description: Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data).
Study: NCT03276312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
Study: NCT04416399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide dry powder inhaler
Description: Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
Study: NCT04634396

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACT Acceptance and Commitment Therapy
Description: 6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools
Study: NCT04786457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10\^3 PFU/mL
Study: NCT03188562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Positron Emission Tomography (PET/CT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Positron Emission Tomography (PET/CT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA, EUS-NA
Description: Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEMLA
Description: Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
Study: NCT02430350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Edaravone Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edaravone Injection
Study: NCT01475604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ivivi Torino II
Description: Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ivivi Torino II
Description: Sham treatment for 4 weeks post-surgery
Study: NCT02113579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Mouth Rinse 12027-033
Description: After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouth Rinse
Description: After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
Study: NCT04450563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day outpatient intervention
Description: The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day outpatient intervention
Description: The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day outpatient intervention
Description: The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
Study: NCT04229953

Intervention type: DEVICE
Intervention: US scan with 3D/4D VRU software
Description: Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done.
Study: NCT01462136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHN-490 Injection
Description: 7.5 mg/kg single dose administered intravenously over 30 minutes
Study: NCT05831826

Intervention type: BIOLOGICAL
Intervention: the inactivated COVID-19 vaccines
Description: receive the doses of inactivated COVID-19 vaccines

Intervention type: BIOLOGICAL
Intervention: the inactivated COVID-19 vaccines
Description: receive the doses of inactivated COVID-19 vaccines
Study: NCT02901496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise Training
Description: Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance Exercise Training
Description: Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Exercise
Description: Control to exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Exercise
Description: Control to exercise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
Study: NCT00528983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) Azacitidine
Description: 75 mg/day for first 7 days of 28 day cycle for 1 cycle only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
Study: NCT03137186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
Study: NCT03194178

Intervention type: OTHER
Intervention: Pierre Robin sequence patients
Description: 4 questionnaires will be completed by the patient :~* Kidscreen 52 (generic quality of life questionnaire)~* Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~* Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~* MDI-C (composite depression scale for minors)
Study: NCT00268437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
Study: NCT00525044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01489202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: platinum chromium everolimus-eluting stent
Description: An everolimus-eluting stent with a platinum chromium platform

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt chromium everolimus-eluting stent
Description: An everolimus-eluting stent with cobalt chromium platform
Study: NCT02036632

Intervention type: DEVICE
Group type: OTHER
Intervention: Eye Patching
Study: NCT01033656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: 100 mg subcutaneous injection daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: comparators
Description: po drugs, comparators
Study: NCT01704287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin per institutional standard

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel per institutional standard

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine per institutional standard

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide per institutional standard

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide per institutional standard

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide per institutional standard
Study: NCT04100629

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: digital support: text messages
Description: In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital support: text messages
Description: In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
Study: NCT04042740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P)
Description: Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
Study: NCT02454335

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy
Description: The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy
Description: The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
Study: NCT03207113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ned
Description: Prostate cancer survivorship application.
Study: NCT02611661

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI
Study: NCT01246596

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental root planing
Description: The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,\[1\] thus helping to establish a periodontium that is free of disease.\[2\]
Study: NCT02611661

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Percutaneous ablation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Percutaneous ablation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Study: NCT03700151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment for Children with Severe Speech Sound Disorders
Description: The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
Study: NCT03713034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PlayTest!
Description: Participants in the PlayTest! intervention arm played the game on their assigned iPads once per week for an hour over the course of 4-5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control games
Description: Participants in the control arm played the games on their assigned iPads once per week for an hour over the course of 4-5 weeks.